{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:11:01Z","timestamp":1793657461137,"version":"4.5.1"},"reference-count":198,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.mayocp.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T20:54:53Z","timestamp":1622580893000},"page":"1546-1577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar F.","family":"Abou Ezzeddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9619-7802","authenticated-orcid":false,"given":"Michelle","family":"Mauermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustaqueem","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy T.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-3376","authenticated-orcid":false,"given":"Ellen D.","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7972-3556","authenticated-orcid":false,"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-4580","authenticated-orcid":false,"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie L.","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam A.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-4620","authenticated-orcid":false,"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-3970","authenticated-orcid":false,"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2011-07-365510","article-title":"Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue","volume":"119","author":"Brambilla","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2021.03.012_bib5","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry\u2013based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2021.03.012_bib6","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 [erratum appears in Mayo Clin Proc. 2013;88(7):777]","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ajh.23827","article-title":"Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias","volume":"89","author":"Kourelis","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib16","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib20","first-page":"472","article-title":"A\u00a0modern primer on light chain amyloidosis in 592 patients with mass spectrometry\u2013verified typing [erratum appears in Mayo Clin Proc. 2019;94(6):1121]","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib24","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.510250122","article-title":"Hepatic amyloidosis: clinical appraisal in 77 patients","volume":"25","author":"Gertz","year":"1997","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.mayocp.2021.03.012_bib26","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2010-02-267708","article-title":"Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay","volume":"116","author":"Kristen","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib27","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.mayocp.2021.03.012_bib28","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.mayocp.2021.03.012_bib29","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib30","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3324\/haematol.2011.040493","article-title":"Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis","volume":"96","author":"Wechalekar","year":"2011","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.mayocp.2021.03.012_bib31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A\u00a0practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"Fernandez de Larrea","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Schonland","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cjp2.126","article-title":"The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis","volume":"5","author":"Rezk","year":"2019","journal-title":"J\u00a0Pathol Clin Res"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.mayocp.2021.03.012_bib35","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.mayocp.2017.09.016","article-title":"Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis","volume":"92","author":"Geller","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.1016\/j.mayocp.2021.03.012_bib36","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib38","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib39","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1002\/ajh.25440","article-title":"Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis","volume":"94","author":"Sidiqi","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.mayocp.2017.02.016","article-title":"Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"92","author":"Kourelis","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib41","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/S2352-3026(15)00068-X","article-title":"Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study","volume":"2","author":"Mahmood","year":"2015","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib42","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib43","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib44","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib45","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mayocp.2021.03.012_bib46","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","article-title":"Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases","volume":"68","author":"Kyle","year":"1986","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib48","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.0b013e3181d55f4d","article-title":"Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis","volume":"74","author":"Dingli","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/mcp.2010.0480","article-title":"Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score","volume":"86","author":"Kumar","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"10038","key":"10.1016\/j.mayocp.2021.03.012_bib50","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.mayocp.2021.03.012_bib51","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987\u20132019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ejh.12282","article-title":"Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant","volume":"92","author":"Warsame","year":"2014","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib55","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib56","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","article-title":"Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"107","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2021.03.012_bib57","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2021.03.012_bib58","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1182\/blood.V114.22.2796.2796","article-title":"A\u00a0new staging system for AL amyloidosis incorporating serum free light chains, cardiac troponin-T and NT-ProBNP","volume":"114","author":"Wechalekar","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib59","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib60","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.echo.2010.03.027","article-title":"Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study","volume":"23","author":"Bellavia","year":"2010","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib62","doi-asserted-by":"crossref","first-page":"e006588","DOI":"10.1161\/CIRCIMAGING.117.006588","article-title":"Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis","volume":"11","author":"Milani","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"issue":"36","key":"10.1016\/j.mayocp.2021.03.012_bib63","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.mayocp.2021.03.012_bib64","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2018.1443439","article-title":"Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome","volume":"25","author":"Tovar","year":"2018","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib66","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis [erratum appears in Leukemia. 2020;34(10):2819]","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib67","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2016.05.027","article-title":"The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation","volume":"22","author":"Dittus","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.mayocp.2021.03.012_bib68","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas","year":"2020","journal-title":"Amyloid"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib70","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib71","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib72","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/j.clml.2018.07.292","article-title":"Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p","volume":"18","author":"Wong","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib73","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib74","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"25","key":"10.1016\/j.mayocp.2021.03.012_bib75","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib76","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib78","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-020-00354-7","article-title":"Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"10","author":"Sarosiek","year":"2020","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.mayocp.2021.03.012_bib79","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2016-06-721878","article-title":"The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib81","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13506129.2020.1802713","article-title":"Next generation flow cytometry for MRD detection in patients with AL amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib84","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V52.4.818.818","article-title":"Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo","volume":"52","author":"Kyle","year":"1978","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib86","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/0002-9343(85)90521-2","article-title":"Primary systemic amyloidosis. Comparison of melphalan\/prednisone versus colchicine","volume":"79","author":"Kyle","year":"1985","journal-title":"Am J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2021.03.012_bib87","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib88","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib89","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"32","key":"10.1016\/j.mayocp.2021.03.012_bib90","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.16143","article-title":"A\u00a024-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom","volume":"187","author":"Sharpley","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib92","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41409-019-0447-y","article-title":"Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis","volume":"54","author":"Gutierrez-Garcia","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib93","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.mayocp.2021.03.012_bib94","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2012-09-457341","article-title":"High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center","volume":"120","author":"Tsai","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/10428190701684518","article-title":"Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis","volume":"49","author":"Gertz","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib96","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","article-title":"Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome","volume":"33","author":"Mollee","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.mayocp.2021.03.012_bib98","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib99","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1046\/j.1523-1755.2003.00936.x","article-title":"Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis","volume":"63","author":"Fadia","year":"2003","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib100","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.mayocp.2021.03.012_bib101","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bmt.1704691","article-title":"Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib102","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/bmt.2013.53","article-title":"Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center","volume":"48","author":"Dispenzieri","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib103","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2018.07.010","article-title":"Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation","volume":"24","author":"Afrough","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.mayocp.2021.03.012_bib104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib105","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3324\/haematol.2018.213900","article-title":"Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial","volume":"104","author":"Minnema","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib106","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib107","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2019.08.016","article-title":"Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis","volume":"26","author":"Landau","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.mayocp.2021.03.012_bib108","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/bloodadvances.2020002219","article-title":"Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis","volume":"4","author":"Basset","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-018-0137-9","article-title":"Deferred autologous stem cell transplantation in systemic AL amyloidosis","volume":"8","author":"Manwani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bmt.1705746","article-title":"Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis [erratum appears in Bone Marrow Transplant. 2007;40(6):607]","volume":"40","author":"Sanchorawala","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib111","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone\u00a0+\/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib112","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2012.274","article-title":"Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis","volume":"27","author":"Landau","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib113","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ajh.25572","article-title":"Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis","volume":"94","author":"Al Saleh","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mayocp.2021.03.012_bib114","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib117","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1523-1755.2003.00813.x","article-title":"High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis\u2013associated end-stage renal disease","volume":"63","author":"Casserly","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib118","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.bbmt.2018.12.003","article-title":"Autologous stem cell transplant for IgM-associated amyloid light-chain amyloidosis","volume":"25","author":"Sidiqi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.mayocp.2021.03.012_bib119","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.mayocp.2021.03.012_bib120","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2021.03.012_bib121","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib122","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41409-017-0020-5","article-title":"Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis","volume":"53","author":"Sidana","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib123","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib124","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib125","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib126","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib127","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjh.16122","article-title":"Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy","volume":"187","author":"Manwani","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib128","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1080\/10428194.2020.1737688","article-title":"Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement","volume":"61","author":"Deshpande","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib129","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.mayocp.2021.03.012_bib130","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","article-title":"European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis","volume":"34","author":"Sachchithanantham","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/13506129.2015.1092433","article-title":"Clinical presentation and treatment responses in IgM-related AL amyloidosis","volume":"22","author":"Sissoko","year":"2015","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib132","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MD.0b13e31816c43b6","article-title":"The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients","volume":"87","author":"Terrier","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib133","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2008-02-138156","article-title":"AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome","volume":"112","author":"Wechalekar","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib134","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","article-title":"When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression","volume":"3","author":"Palladini","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/bloodadvances.2018021261","article-title":"Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details","volume":"3","author":"Sanchorawala","year":"2019","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.mayocp.2021.03.012_bib136","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2017-05-783415","article-title":"Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis","volume":"130","author":"Hwa","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib137","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2017.1411796","article-title":"Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis","volume":"25","author":"Hari","year":"2018","journal-title":"Amyloid"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib139","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 Study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib140","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A\u00a0prospective phase 2 of daratumumab in previously treated systemic light chain amyloidosis (AL) patients","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib141","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib142","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib143","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib144","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A\u00a0phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis [erratum appears in Blood. 2020;135(13):1071]","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2021.03.012_bib145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib146","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib147","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib148","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2021.03.012_bib149","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3324\/haematol.2013.084574","article-title":"Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement","volume":"98","author":"Dinner","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.mayocp.2021.03.012_bib150","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A\u00a0phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2021.03.012_bib151","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.mayocp.2021.03.012_bib152","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib153","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2012.073593","article-title":"A\u00a0phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis","volume":"98","author":"Palladini","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib154","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.2012.075192","article-title":"Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial","volume":"98","author":"Sanchorawala","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.mayocp.2021.03.012_bib155","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mayocp.2021.03.012_bib156","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A\u00a0phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib157","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2021.03.012_bib158","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib159","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib160","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bmt.2010.239","article-title":"A\u00a0second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis","volume":"46","author":"Quillen","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib161","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clml.2018.08.021","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma","volume":"19","author":"Iqbal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"10.1016\/j.mayocp.2021.03.012_bib162","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib163","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1378\/chest.124.3.969","article-title":"Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis","volume":"124","author":"Berk","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib164","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"74","author":"Dubrey","year":"1995","journal-title":"Br Heart J"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib165","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib166","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib167","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"issue":"13, pt 1","key":"10.1016\/j.mayocp.2021.03.012_bib168","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"issue":"8, pt 1","key":"10.1016\/j.mayocp.2021.03.012_bib169","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"issue":"12","key":"10.1016\/j.mayocp.2021.03.012_bib171","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehp592","article-title":"Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death","volume":"31","author":"Lin","year":"2010","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.mayocp.2021.03.012_bib172","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/clc.20389","article-title":"Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review","volume":"32","author":"Dhoble","year":"2009","journal-title":"Clin Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib173","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1253\/circj.72.331","article-title":"Attenuation of diastolic heart failure and life-threatening ventricular tachyarrhythmia after peripheral blood stem cell transplantation combined with cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis","volume":"72","author":"Yaoita","year":"2008","journal-title":"Circ J"},{"issue":"7","key":"10.1016\/j.mayocp.2021.03.012_bib174","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"18","key":"10.1016\/j.mayocp.2021.03.012_bib175","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A\u00a0study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib176","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archneur.63.4.noc50340","article-title":"Pyridostigmine treatment trial in neurogenic orthostatic hypotension","volume":"63","author":"Singer","year":"2006","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib177","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1074\/jbc.M110.178376","article-title":"Effect of tetracyclines on the dynamics of formation and destructuration of \u03b22-microglobulin amyloid fibrils","volume":"286","author":"Giorgetti","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"25","key":"10.1016\/j.mayocp.2021.03.012_bib178","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2021.03.012_bib179","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib180","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib181","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib182","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis [erratum appears in Kidney Int. 2019;96(3):796]","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib183","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.kint.2020.06.036","article-title":"A\u00a0study from the Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis","volume":"99","author":"Heybeli","year":"2021","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.mayocp.2021.03.012_bib184","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2021.03.012_bib185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1378\/chest.06-3118","article-title":"External beam radiation therapy for tracheobronchial amyloidosis","volume":"132","author":"Neben-Wittich","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.mayocp.2021.03.012_bib186","first-page":"252","article-title":"Localised amyloidosis of the urinary bladder: a case report and review of treatment","volume":"13","author":"Shittu","year":"1994","journal-title":"West Afr J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib187","first-page":"1018","article-title":"Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy","volume":"168","author":"Malek","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.mayocp.2021.03.012_bib188","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.4065\/75.12.1264","article-title":"Primary localized amyloidosis of the urinary bladder: a case series of 31 patients","volume":"75","author":"Tirzaman","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib189","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOO.0000000000000579","article-title":"Laryngeal amyloidosis","volume":"27","author":"Burns","year":"2019","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib190","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4065\/75.11.1148","article-title":"Tracheobronchial amyloidosis","volume":"75","author":"Capizzi","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.mayocp.2021.03.012_bib191","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.mayocp.2021.03.012_bib192","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A\u00a0matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib193","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/13506129.2019.1594759","article-title":"Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study","volume":"26","author":"Shen","year":"2019","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.mayocp.2021.03.012_bib194","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.clml.2019.11.005","article-title":"Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes","volume":"20","author":"Diaz-Pallares","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.mayocp.2021.03.012_bib196","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.mayocp.2021.03.012_bib197","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.03.012_bib198","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hon.2677","article-title":"Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden","volume":"37","author":"Schwotzer","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:36:44Z","timestamp":1758418604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619621002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":198,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0025619621002287"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.03.012","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}